Cas:86270-03-3 3-(Trifluoromethoxy)benzoyl chloride manufacturer & supplier

We serve Chemical Name:3-(Trifluoromethoxy)benzoyl chloride CAS:86270-03-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

3-(Trifluoromethoxy)benzoyl chloride

Chemical Name:3-(Trifluoromethoxy)benzoyl chloride
CAS.NO:86270-03-3
Synonyms:7006050;m-(Trifluoromethoxy)benzoyl chloride;Benzoyl chloride, 3-(trifluoromethoxy)-;MFCD00061268;GVR COXFFF;3-(Trifluoromethoxy)benzoyl chloride
Molecular Formula:C8H4ClF3O2
Molecular Weight:224.564
HS Code:2918990090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:204.1±35.0 °C at 760 mmHg
Density:1.4±0.1 g/cm3
Index of Refraction:1.471
PSA:26.30000
Exact Mass:223.985199
LogP:3.41

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:3265
Packing Group:II


Contact us for information like 7006050 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(Trifluoromethoxy)benzoyl chloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00061268 Use and application,MFCD00061268 technical grade,usp/ep/jp grade.


Related News: The analysis examined disease manifestations in the two most commonly impacted organ domains in SLE. Anifrolumab is a potential first-in-class type I interferon inhibitor. cmda manufacturers For example, by using molecular modeling tools to achieve rapid de novo design of new enzymes, it may be possible to increase activity, enhance temperature stability, or improve solvent compatibility to better align with the process in question. Cinnamyl butanoate suppliers In Massachusetts, where the bulk of Takeda’s U.S. operations are based since the Shire buyout, the Japanese pharma has been swiftly ramping up its cell therapy ambitions. In September, the company cut the ribbon on a new 24,000-square-foot R&D manufacturing center in Boston, which it said at the time would handle clinical development for three ongoing pipeline programs and two other prospects pegged to enter clinical development by the end of 2021. 2,4-Dihydroxy-5-isopropylbenzoic acid vendor & factory.